JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Fetal and neonatal effects of anticoagulants used in pregnancy: a review.

There are several relative (promising regarding a reduction in placenta-mediated complications such as preeclampsia) and absolute (e.g. a recurrent or recent thromboembolic event, mechanical heart valves) reasons for use of anticoagulant drugs during pregnancy. Warfarin readily crosses the placenta because of its low molecular weight, and is associated with a distinctive embryopathy known as fetal warfarin syndrome when exposure occurs between the sixth and twelfth weeks of gestation. Warfarin embryopathy may be avoided by stopping warfarin and switching to heparin when pregnancy is achieved or as soon as possible after conception. Heparins, unfractionated heparin and low molecular weight heparin are the preferred agents for anticoagulation in pregnancy because they show no transplacental passage due to their high molecular weights. Both heparins and warfarin are safe for the infant during breastfeeding. Aspirin is prescribed with increasing frequency to reduce the risk of miscarriage and poor pregnancy outcome. Although aspirin crosses the placenta, it is safe in low doses. However, the safety of higher doses of aspirin during the first pregnancy is uncertain.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app